Assay Descriptions & Downloads


Meetings / Conferences Meet us at the IBC Drug Discovery and Development Conference Aug 4-7. Buzz Brown to speak Aug 6 at 10:10AM Ion Channels Play Key Role in R&D Genetic Enginering News article (Jun 1 2008 (Vol. 28, No. 11)). ChanTest profiled. Spotlight Paper Alfuzosin delays cardiac repolarization by a novel mechanism (2008) J Pharmacol Exp Ther. 324(2):427-433

ChanTest sets the standard in preclinical cardiac risk assessment

We design our comprehensive range of ion channel assays, follow-up models, and consultation services to give you the early answers you need to identify the most-promising drug targets, and eliminate those that could be harmful – before you invest millions on clinical trials.
Click on the PDF icons below to download information sheets on our GLP and Non-GLP safety assays.

GLP – assays required for IND submission:

GLP hERG IC₅₀ – tightest IC₅₀s ever published (Kirsch et al. J Pharm Tox Method 2004)

GLP Dose Solution Analysis – our synchronized process identifies compound stability issues

GLP – recommended repolarization/follow-up assays:

GLP APD Purkinje fiber assay with time-matched vehicle controls for rundown & stability (canine & rabbit available) – Identifies which channels are affecting the action potential duration (mixed ion channel effects)

GLP CT-QT isolated heart assay measuring QT, contractility, MAPD, & other parameters with time-matched vehicle controls for rundown & stability (isolated rabbit heart) – Evaluates mixed ion channel effects & provides a comprehensive assessment of the effects of drugs on cardiac activity

GLP Dose Solution Analysis – our synchronized process identifies compound stability issues

GLP Cardiac Channel Panel^TM (auto-patch) or manual patch clamp cardiac channel IC₅₀ counter screen – identifies the cardiac ion channels that determine repolarization risk

Non-GLP – basic ion channel profiling screens:

Manual patch clamp screen (1-2 concentration screen for each compound) – tabular results, ranked to identify the safety of drug candidates

FASTPatch automated patch screen (1-2 concentration screen for each compound) – tabular results, ranked to identify the safety of drug candidates

Manual patch clamp IC₅₀ screen (concentration-response curve & IC₅₀ 3+ concentration screen for each compound) – determines the safety of therapeutic doses of drug candidates

Non-GLP – additional hERG screens:

HERG-Lite screen – economically identifies hidden hERG trafficking inhibition

FAST & Lite^TM (FASTPatch^® & HERGLite^®) – Provides a comprehensive valuation of hERG inhibition – both direct block & defective trafficking

Non-GLP – repolarization or follow-up screens:

APD Purkinje fiber assay with time-matched vehicle controls for rundown & stability (canine & rabbit available) – Identifies which channels are affecting the action potential duration (mixed ion channel effects)

CT-QT isolated heart assay measuring QT, contractility, MAPD, & other parameters with time-matched vehicle controls for rundown & stability (isolated rabbit heart) – Evaluates mixed ion channel effects & provides a comprehensive assessment of the effects of drugs on cardiac activity

Cardiac Channel Panel^TM (auto-patch) or manual patch clamp cardiac channel IC₅₀ counter screen – identifies the cardiac ion channels that determine repolarization risk

Non-GLP – other assays

S7A Channel Profiling Panel^TM – FDA Critical Path tools for predicting safety & efficacy